高级检索
当前位置: 首页 > 详情页

SMYD3 Promotes Immune Evasion in Clear Cell Renal Cell Carcinoma via SREBP1-Mediated Transactivation of CD47

文献详情

资源类型:
Pubmed体系:
机构: [1]Thoracic Surgery Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, 250117, China. [2]Department of Urology, Qilu Hospital of Shandong University, Jinan, 2500112, China. [3]Department of Pathology, Qilu Hospital of Shandong University, Jinan, 250012, China. [4]Department of Hematology, The Second Hospital of Shandong University, Jinan, 250033, China. [5]Department of Urology, The First Affiliated Hospital of Shandong First Medical University Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Organ Transplantation and Nephrosis, Shandong Institute of Nephrology, Jinan, 250013, China. [6]Translational Chinese Medicine Key Laboratory of Sichuan Province, Sichuan Institute for Translational Chinese Medicine, Sichuan Academy of Chinese Medicine Sciences, Chengdu, 610042, China. [7]School of Nursing, Beijing University of Chinese Medicine, Beijing, 100191, China. [8]Department of Breast Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China. [9]Department of Pathology, Peking University People's Hospital, Beijing, 100044, China.
出处:

关键词: clear cell renal cell carcinoma immune evasion SMYD3/SREBP1/CD47 signaling

摘要:
Cancer cell-intrinsic features (e.g., genetic aberrations and dysregulation of signaling pathways) play pivotal roles in orchestrating the composition and functional state of the immune landscape, which in turn impact tumor progression and response to immunotherapy. Here, it is discovered that dysregulation of cancer cell-intrinsic SET and MYND domain-containing protein 3 (SMYD3) leads to the orchestration of an immunosuppressive microenvironment and the impairment of responses to PD-1 blockade by reprogramming the infiltration of immune cells in the tumor microenvironment of clear cell renal cell carcinoma (ccRCC). SMYD3 cooperates with Sp1 to transcriptionally promote sterol regulatory element-binding protein 1 (SREBP1) expression by modifying H3-K4 di-/trimethylation and consequently activating the transcription of CD47. CD47, a bridge between innate and adaptive immunity, acts as the downstream effector molecule of the SMYD3 signal to promote the infiltration of T helper 2 (Th2) cells, protecting renal cancer cells from immune attack. In summary, the critical role of the cancer cell-intrinsic SMYD3-SREBP1-CD47 axis is elucidated in regulating the immune microenvironment in ccRCC and provides a potential therapeutic strategy to manipulate the tumor immune milieu in favor of antitumor immunity.© 2025 The Author(s). Advanced Science published by Wiley‐VCH GmbH.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 1 区 综合性期刊
小类 | 1 区 化学:综合 1 区 材料科学:综合 1 区 纳米科技
最新[2025]版:
大类 | 1 区 综合性期刊
小类 | 1 区 化学:综合 1 区 材料科学:综合 1 区 纳米科技
第一作者:
第一作者机构: [1]Thoracic Surgery Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, 250117, China. [2]Department of Urology, Qilu Hospital of Shandong University, Jinan, 2500112, China. [3]Department of Pathology, Qilu Hospital of Shandong University, Jinan, 250012, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:65780 今日访问量:0 总访问量:5151 更新日期:2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号